Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1996 1
1997 1
1998 1
1999 2
2000 2
2001 9
2002 6
2003 9
2004 8
2005 12
2006 8
2007 24
2008 21
2009 21
2010 2
2011 5
2012 3
2013 4
2014 1
2015 1
2016 3
2017 3
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 17587254

135 results

Results by year

Filters applied: . Clear all
Page 1
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P. Andersen O, et al. J Neurol Neurosurg Psychiatry. 2004 May;75(5):706-10. doi: 10.1136/jnnp.2003.010090. J Neurol Neurosurg Psychiatry. 2004. PMID: 15090564 Free PMC article. Clinical Trial.
Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. Hurwitz BJ, et al. Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013. Clin Ther. 2008. PMID: 18640466 Clinical Trial.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Schwid SR, et al. Arch Neurol. 2005 May;62(5):785-92. doi: 10.1001/archneur.62.5.785. Arch Neurol. 2005. PMID: 15883267 Clinical Trial.
135 results